Nurix Therapeutics, Inc.·4

Feb 10, 5:43 PM ET

SANDS ARTHUR T 4

Research Summary

AI-generated summary

Updated

Nurix (NRIX) CEO Arthur T. Sands Receives 562,500-Share Option Award

What Happened Arthur T. Sands (President, CEO and Director) received a derivative equity award of 562,500 shares on February 10, 2026. The filing reports the transaction price as $0.00 (i.e., a grant/award of a derivative instrument rather than a cash purchase or sale). No cash was paid and no shares were sold in this filing.

Key Details

  • Transaction date: 2026-02-10; transaction type: Grant/Award (code A).
  • Amount: 562,500 derivative shares; reported price: $0.00.
  • Shares owned after transaction: Not specified in the provided filing.
  • Footnote: The option vests 1/36 of the total shares monthly beginning March 10, 2026, and fully vests on February 9, 2029, subject to continued service.
  • Filing timeliness: Reported and filed on 2026-02-10; no late filing indicated.
  • No 10b5-1 plan, tax-withholding sale, or immediate exercise/sale reported.

Context This is a time-based equity grant (typical executive compensation) that vests over three years; it is not an immediate purchase or sale and does not create freely tradable shares until vesting/exercise. Such grants align executive incentives with company performance and retention but do not by themselves indicate insider buying or selling sentiment.